China Designates Ascentage's Olverembatinib Cancer Therapy as Breakthrough Therapy

MT Newswires Live

Mar 06, 2025

The Center for Drug Evaluation of China's National Medical Products Administration granted Ascentage Pharma Group International's (HKG:6855) olverembatinib its third breakthrough therapy designation, a Thursday bourse filing said.

The designation is for the drug's combination with low-intensity chemotherapy for treating newly-diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, a type of blood cancer caused by a genetic mutation in certain chromosomes.

The drug has been granted breakthrough therapy designation twice before, once in March 2021 for the treatment of patients with chronic-phase chronic myeloid leukemia and then in June 2023 for patients with succinate dehydrogenase-deficient gastrointestinal stromal tumors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2517183402"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2517183402\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2517183402?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-06 14:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2517183402","market":"fut","top_or_hot":-1,"title":"China Designates Ascentage's Olverembatinib Cancer Therapy as Breakthrough Therapy","media":"MT Newswires Live","content":"<html><body><p> The Center for Drug Evaluation of China's National Medical Products Administration granted Ascentage Pharma Group International's (HKG:6855) olverembatinib its third breakthrough therapy designation, a Thursday bourse filing said.</p><p>The designation is for the drug's combination with low-intensity chemotherapy for treating newly-diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, a type of blood cancer caused by a genetic mutation in certain chromosomes.</p><p>The drug has been granted breakthrough therapy designation twice before, once in March 2021 for the treatment of patients with chronic-phase chronic myeloid leukemia and then in June 2023 for patients with succinate dehydrogenase-deficient gastrointestinal stromal tumors.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Designates Ascentage's Olverembatinib Cancer Therapy as Breakthrough Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Designates Ascentage's Olverembatinib Cancer Therapy as Breakthrough Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-06 14:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> The Center for Drug Evaluation of China's National Medical Products Administration granted Ascentage Pharma Group International's (HKG:6855) olverembatinib its third breakthrough therapy designation, a Thursday bourse filing said.</p><p>The designation is for the drug's combination with low-intensity chemotherapy for treating newly-diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, a type of blood cancer caused by a genetic mutation in certain chromosomes.</p><p>The drug has been granted breakthrough therapy designation twice before, once in March 2021 for the treatment of patients with chronic-phase chronic myeloid leukemia and then in June 2023 for patients with succinate dehydrogenase-deficient gastrointestinal stromal tumors.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2517183402","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517183402","pubTimestamp":1741242590,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"The Center for Drug Evaluation of China's National Medical Products Administration granted Ascentage Pharma Group International's  olverembatinib its third breakthrough therapy designation, a Thursday bourse filing said.The designation is for the drug's combination with low-intensity chemotherapy for treating newly-diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, a type of blood cancer caused by a genetic mutation in certain chromosomes.The drug has been granted breakthrough therapy designation twice before, once in March 2021 for the treatment of patients with chronic-phase chronic myeloid leukemia and then in June 2023 for patients with succinate dehydrogenase-deficient gastrointestinal stromal tumors.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","06855":"亚盛医药-B","BK1574":"生物医药B类股"},"translate_title":"中国指定亚盛的Olverembatinib癌症疗法为突破性疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06855":0.9},"content_text":"The Center for Drug Evaluation of China's National Medical Products Administration granted Ascentage Pharma Group International's (HKG:6855) olverembatinib its third breakthrough therapy designation, a Thursday bourse filing said.The designation is for the drug's combination with low-intensity chemotherapy for treating newly-diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, a type of blood cancer caused by a genetic mutation in certain chromosomes.The drug has been granted breakthrough therapy designation twice before, once in March 2021 for the treatment of patients with chronic-phase chronic myeloid leukemia and then in June 2023 for patients with succinate dehydrogenase-deficient gastrointestinal stromal tumors.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}